These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10435880)

  • 21. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
    Peñalva A; Burguera B; Casabiell X; Tresguerres JA; Dieguez C; Casanueva FF
    Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute hyperglycemia and activation of the beta-adrenergic system exhibit synergistic inhibitory actions on growth hormone (GH) releasing hormone-induced GH release.
    Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Park S
    Eur J Endocrinol; 2003 Jun; 148(6):635-40. PubMed ID: 12773135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galanin abolishes the inhibitory effect of cholinergic blockade on growth hormone-releasing hormone-induced secretion of growth hormone in man.
    Chatterjee VK; Ball JA; Proby C; Burrin JM; Bloom SR
    J Endocrinol; 1988 Feb; 116(2):R1-2. PubMed ID: 2450944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone.
    de Vries WR; Schers TJ; Ait Abdesselam S; Osman-Dualeh M; Maitimu I; Koppeschaar HP
    Int J Sports Med; 2003 Apr; 24(3):208-11. PubMed ID: 12740741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.
    Kelijman M; Frohman LA
    J Clin Endocrinol Metab; 1990 Jul; 71(1):157-63. PubMed ID: 1973420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies of growth hormone secretion in calorically restricted dogs: effect of cholinergic agonists and antagonists, glucose and thyrotropin-releasing hormone.
    Arce VM; Cella SG; Locatelli V; Müller EE
    Neuroendocrinology; 1991 May; 53(5):467-72. PubMed ID: 1908062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inhibition of growth hormone (GH) response to GHRH in diabetes mellitus type 1 after blockade of the cholinergic system with pirenzepine].
    Krassowski J; Rogala H; Jeske W; Zgliczyński S
    Pol Arch Med Wewn; 1992 Jul; 88(1):25-9. PubMed ID: 1454656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity.
    Pincelli AI; Rigamonti AE; Scacchi M; Cella SG; Cappa M; Cavagnini F; Müller EE
    Eur J Endocrinol; 2003 Feb; 148(2):237-43. PubMed ID: 12590644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced GH secretion in anorexia nervosa.
    Tamai H; Komaki G; Matsubayashi S; Kobayashi N; Mori K; Nakagawa T; Truong MP; Walter RM; Kumagai LF
    J Clin Endocrinol Metab; 1990 Mar; 70(3):738-41. PubMed ID: 2106528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.
    Popovic V; Leal A; Micic D; Koppeschaar HP; Torres E; Paramo C; Obradovic S; Dieguez C; Casanueva FF
    Lancet; 2000 Sep; 356(9236):1137-42. PubMed ID: 11030292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
    Nam SY; Lee ; Kim KR; Lee HC; Nam MS; Cho JH; Huh KB
    Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency.
    Achermann JC; Brook CG; Hindmarsh PC
    Eur J Endocrinol; 2000 Apr; 142(4):359-64. PubMed ID: 10754477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term recombinant human growth hormone therapy does not modify growth hormone, thyrotropin and prolactin responses to thyrotropin-releasing hormone in adult dialysis patients.
    Iglesias P; Selgas R; Méndez J; Fernández-Reyes MJ; Bajo MA; Aguilera A; Díez JJ
    Nephrol Dial Transplant; 2000 Jun; 15(6):856-61. PubMed ID: 10831641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY; Granda-Ayala R
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
    Alvarez P; Isidro L; Peinó R; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
    Clin Endocrinol (Oxf); 2003 Oct; 59(4):431-6. PubMed ID: 14510904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of pyridostigmine and pirenzepine on GH responses to GHRH in hyperthyroid patients.
    Valcavi R; Dieguez C; Zini M; Page MD; Dotti C; Portioli I; Scanlon MF
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):141-4. PubMed ID: 1934529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The decrease in growth hormone (GH) response after repeated stimulation with GH-releasing hormone is partly caused by an elevation of somatostatin tonus.
    Reichardt B; Schrader M; Mojto J; Mehltretter G; Müller OA; Schopohl J
    J Clin Endocrinol Metab; 1996 May; 81(5):1994-8. PubMed ID: 8626871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The reduced release of GH by GHRH in 8 subjects aged 65-69 years is augmented considerably by rivastigmine, a drug for Alzheimer's disease.
    Obermayr RP; Mayerhofer L; Knechtelsdorfer M; Tragl KH; Geyer G
    Gerontology; 2003; 49(3):191-5. PubMed ID: 12679611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.